RuiXin Medical Secures 2024 Shenzhen Medical Research Special Fund for AI-Powered Vascular Intervention Robot

Recently, RaysightMed, in collaboration with the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, and Nanfang Hospital of Southern Medical University, has successfully obtained approval.The 2024 Shenzhen Medical Research Special Project (hereinafter referred to as "DeepMed Special Project") - Application and Transformation Projects, conducts research on the theme of "Intelligent Interventional Robotics for Cardiovascular and Peripheral Vessels and Their Autonomous Navigation Methods." The implementation of this project,Marks RaysightMed's technological innovation and application transformation achievements in the field of vascular interventional surgical robotics and intelligent healthcare receiving official recognition., which is expected to bring new breakthroughs to the interventional treatment model for cardiovascular and peripheral vascular diseases.

RaysightMed Cardiovascular Interventional Surgical Robot Rendering

The establishment of the Shenzhen Medical Special Project is the implementation by the Shenzhen Municipal Government."Four Orientations," further building Shenzhen into a highland for medical research, improving clinical research and diagnostic treatment standards, and strengthening the innovation-driven function of the biopharmaceutical industry are important initiatives. It is reported that the review criteria for the Shenzhen Medical Special Fund (Shenmed) are extremely strict, with fierce competition among projects and a funding rate of less than 10%. The approval of this project fully demonstrates that RaysightMed possesses industry-leading advantages in both technological innovation and industrial application.

Abundant Achievements in Technological Innovation

Developing Intelligent Systems for Vascular Interventional Surgical Robots

The vascular interventional surgical robot independently developed by RaysightMed provides doctors with intelligent "brain," "eyes," and "hands."Provided a strong guarantee for the precision and stability of surgical operations.。The product adoptsSeparate Master-Slave StructureDoctors can complete the entire process of vascular interventional surgery, including instrument use and operation, outside the operating room, effectively avoiding X-ray radiation.

Secondly, RaysightMed Cardiovascular Interventional Surgical Robot SupportsMulti-device collaborative operation, enabling automated and high-precision delivery of guiding catheters, guidewires, and instrument catheters, completing the majority of routine vascular interventional surgical procedures.Due to the搭载 ofIndustry-Leading Bionic Haptic Force Feedback SystemRaysightMed's cardiovascular interventional surgical robot can also help doctors feel the force interaction between the device and blood vessels in real time, as well as provide imaging feedback, thereby achieving highly precise control.Balloon, stent catheter manipulation achieves sub-millimeter level positioning accuracy。In May 2023, the RaysightMed vascular interventional surgery robot successfully completed animal experiments, not only showcasing RaysightMed's profound technical accumulation in the field of vascular interventional surgery robots but also laying a solid foundation for future clinical applications.

Promote Application Transformation

Accelerating Inclusive Healthcare with Technology

As of now, RaysightMed has independently developed and launched the non-invasive coronary blood supply function assessment platform, Rui Xin Score.RuiXin-FFR, RaysightMed's AngioQFA100 FFR Angiography-Assisted Diagnostic System, and vascular interventional surgical robots, among other products, are dedicated to providing an AI + surgical robot integrated hardware-software intelligent diagnosis and treatment platform for coronary applications in clinical settings. The company holds 11 NMPA certificates and 1 EU CE certificate, with over 200 patents applied for and granted. It has been repeatedly awarded key national R&D programs and the Peacock Team Project, while also undertaking major projects such as China’s National Key Special Projects and Shenzhen Medical Academy special projects. The company's products have been introduced in more than 800 tertiary hospitals across China, and it has completed five rounds of financing led by Matrix Partners, Tencent, SDIC Venture Capital, and others. As a result, it has grown into a leading potential unicorn enterprise in its field.

With the global aging population and changes in lifestyle, the incidence of cardiovascular diseases is increasing year by year. "Chinese Circulation Journal"Report Published in July 2024 Shows That Currently, the Number of People with Cardiovascular Diseases in China is 330 Million. In the Mortality Composition of Urban and Rural Residents in China, Cardiovascular Diseases Rank First, Accounting for 2 out of Every 5 Deaths. This Indicates That the Demand for Cardiovascular Interventional Treatment Devices in China Is Expected to Continue Growing in the Future. However, Traditional Vascular Intervention Procedures Still Face Many Challenges, Including Long Learning Curves for Doctors, High Surgical Thresholds, Inaccurate Operations, Radiation Exposure, and the Burden of Wearing Lead Aprons. The RaysightMed Vascular Interventional Robotic System Can Effectively Overcome These Bottlenecks, Thus Having Broad Application Prospects.

Through the approval of Shenzhen Medical Research Special Fund project, RaysightMed will further promote the research on cardiovascular and peripheral vascular interventional surgical robots.Provide highly precise and intelligent integrated solutions for the treatment of cardiovascular diseases, accelerate the digital and intelligent system construction in hospitals, and help improve surgical quality.. In addition, the RaysightMed cardiovascular interventional surgical robot can also be used through5G Technology Enables Remote Surgery, Further Assists in Hierarchical Diagnosis and Treatment, Allows High-Quality Medical Resources to Reach Lower Levels, Addresses the Imbalance of Medical Resource Distribution, and Enables More Urban and Rural Residents to Benefit from Premium Medical Resources.